Danaher Life Sciences — Goodwill increased by 0.1% to $12.86B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.5%, from $12.31B to $12.86B. Over 4 years (FY 2021 to FY 2025), Life Sciences — Goodwill shows a downward trend with a -18.3% CAGR.
A large goodwill balance relative to total assets indicates a strategy heavily reliant on acquisitions for growth.
The premium paid over the fair value of net assets during the acquisition of businesses within the Life Sciences segment...
Common in acquisitive companies; peers with similar M&A history will show significant goodwill on their balance sheets.
dhr_segment_life_sciences_goodwill| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.03B | $31.76B | $31.64B | $31.16B | $30.00B | $29.15B | $8.31B | $8.32B | $8.28B | $8.23B | $12.22B | $12.11B | $12.09B | $12.71B | $12.31B | $12.51B | $12.88B | $12.84B | $12.86B |
| QoQ Change | — | +22.0% | -0.4% | -1.5% | -3.7% | -2.9% | -71.5% | +0.1% | -0.5% | -0.6% | +48.5% | -0.9% | -0.2% | +5.1% | -3.2% | +1.6% | +3.0% | -0.3% | +0.1% |
| YoY Change | — | — | — | — | +15.3% | -8.2% | -73.7% | -73.3% | -72.4% | -71.8% | +47.0% | +45.6% | +46.0% | +54.5% | +0.7% | +3.3% | +6.5% | +1.0% | +4.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.